# Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

> **NCT07213895** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 14 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Empagliflozin/Linagliptin/Metformin HCL
- **DRUG:** Trijardy® XR Extended release film coated tablets

## Key facts

- **NCT ID:** NCT07213895
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-21
- **Primary completion:** 2025-09-15
- **Final completion:** 2025-09-18
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213895, "Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07213895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*